Novartis Faces Setback with MorphoSys Acquisition as Safety Concerns Delay Key Drug Approval Plans
In a turn of events that could reshape Novartis' $2.9 billion acquisition of German biotech MorphoSys, the Swiss pharmaceutical giant ...
In a turn of events that could reshape Novartis' $2.9 billion acquisition of German biotech MorphoSys, the Swiss pharmaceutical giant ...
